Literature DB >> 25297324

Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening.

Aniek Boers1, Rong Wang1, Lorian Slagter-Menkema2, Bettien M van Hemel2, Hilde Ghyssaert3, Ate G J van der Zee1, G Bea A Wisman1, Ed Schuuring4.   

Abstract

This study demonstrates that both the clinical sensitivity and specificity of the Cervista HPV HR test for high-risk human papillomavirus (HPV) detection are not inferior to those of the Hybrid Capture 2 (HC2) test. The intra- and interlaboratory reproducibilities of Cervista were 92.0% (kappa, 0.83) and 90.4% (kappa, 0.80), respectively. The Cervista HPV HR test fulfills all the international HPV test requirements for cervical primary screening purposes.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Year:  2014        PMID： 25297324      PMCID： PMC4313325          DOI： 10.1128/JCM.02716-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

Review 1.  Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force.

Authors:  Evelyn P Whitlock; Kimberly K Vesco; Michelle Eder; Jennifer S Lin; Caitlyn A Senger; Brittany U Burda
Journal:  Ann Intern Med       Date:  2011-10-17       Impact factor: 25.391

2.  Rate of detection of high-risk HPV with two assays in women ≥ 30 years of age.

Authors:  Neil B Quigley; Nicholas T Potter; Mamatha Chivukula; Mirna Z Knight; James R Welch; Marilyn C Olson
Journal:  J Clin Virol       Date:  2011-07-02       Impact factor: 3.168

3.  Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology.

Authors:  Elizabeth M Kurian; Mandi-Lee Caporelli; Stephen Baker; Bruce Woda; Ediz F Cosar; Lloyd Hutchinson
Journal:  Am J Clin Pathol       Date:  2011-11       Impact factor: 2.493

4.  Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens.

Authors:  Kenneth E Youens; Gregory A Hosler; Paula J Washington; E Patrick Jenevein; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

5.  A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study.

Authors:  Jerome L Belinson; Ruifang Wu; Suzanne E Belinson; Xinfeng Qu; Bin Yang; Hui Du; Ruosong Wu; Chun Wang; Lijie Zhang; Yanqiu Zhou; Ying Liu; Robert G Pretorius
Journal:  Am J Clin Pathol       Date:  2011-05       Impact factor: 2.493

6.  Age-stratified performance of the Cervista HPV 16/18 genotyping test in women with ASC-US cytology.

Authors:  Mark H Einstein; Francisco A R Garcia; Amy L Mitchell; Stephen P Day
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-28       Impact factor: 4.254

7.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening.

Authors:  Jack Cuzick; Christine Clavel; Karl-Ulrich Petry; Chris J L M Meijer; Heike Hoyer; Samuel Ratnam; Anne Szarewski; Philippe Birembaut; Shalini Kulasingam; Peter Sasieni; Thomas Iftner
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

8.  Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study.

Authors:  Stephen P Day; Angela Hudson; Andrea Mast; Tamara Sander; Michelle Curtis; Sarah Olson; LuAnne Chehak; Neil Quigley; Joellen Ledford; Belinda Yen-Lieberman; Debra Kohn; Denise I Quigley; Marilyn Olson
Journal:  J Clin Virol       Date:  2009-07       Impact factor: 3.168

9.  Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.

Authors:  Chris J L M Meijer; Johannes Berkhof; Philip E Castle; Albertus T Hesselink; Eduardo L Franco; Guglielmo Ronco; Marc Arbyn; F Xavier Bosch; Jack Cuzick; Joakim Dillner; Daniëlle A M Heideman; Peter J F Snijders
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

10.  Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.

Authors:  Aniek Boers; Lorian Slagter-Menkema; Bettien M van Hemel; Jerome L Belinson; Teus Ruitenbeek; Henk J Buikema; Harry Klip; Hilde Ghyssaert; Ate G J van der Zee; Geertruida H de Bock; G Bea A Wisman; Ed Schuuring
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240
View more
  8 in total

1.  Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.

Authors:  Rong Wang; Xiao-Lei Guo; G Bea A Wisman; Ed Schuuring; Wen-Feng Wang; Zheng-Yu Zeng; Hong Zhu; Shang-Wei Wu
Journal:  BMC Infect Dis       Date:  2015-07-04       Impact factor: 3.090

2.  The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening.

Authors:  Ditte Ejegod; Fabio Bottari; Helle Pedersen; Maria Teresa Sandri; Jesper Bonde
Journal:  J Clin Microbiol       Date:  2016-06-15       Impact factor: 5.948

Review 3.  HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions.

Authors:  Luciano Mariani; Maria Teresa Sandri; Mario Preti; Massimo Origoni; Silvano Costa; Paolo Cristoforoni; Fabio Bottari; Mario Sideri
Journal:  J Cancer       Date:  2016-01-01       Impact factor: 4.207

4.  Role of high-risk human papillomavirus in the etiology of oral and oropharyngeal cancers in Thailand: A case-control study.

Authors:  Adit Chotipanich; Surattaya Siriarechakul; On-Ong Mungkung
Journal:  SAGE Open Med       Date:  2018-03-19

5.  Increased proportions of HIV-infected women met cervical cancer screening guideline in 2016.

Authors:  Debbie Y Mohammed; Prerak Shukla; Yuriy Babayants; Raymund Sison; Jihad Slim
Journal:  Int J Womens Health       Date:  2018-02-16

6.  Cervical cancer screening using the Cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China.

Authors:  Guanyu Ruan; Yiyi Song; Binhua Dong; Xiaodan Mao; Fen Lin; Yafang Kang; Shuxia Xu; Xianjing Chen; Qibin Wu; Pengming Sun
Journal:  Cancer Manag Res       Date:  2018-09-04       Impact factor: 3.989

Review 7.  Current Technologies and Recent Developments for Screening of HPV-Associated Cervical and Oropharyngeal Cancers.

Authors:  Sunny S Shah; Satyajyoti Senapati; Flora Klacsmann; Daniel L Miller; Jeff J Johnson; Hsueh-Chia Chang; M Sharon Stack
Journal:  Cancers (Basel)       Date:  2016-09-09       Impact factor: 6.639

8.  Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.

Authors:  Ditte Møller Ejegod; Camilla Lagheden; Ramya Bhatia; Helle Pedersen; Elia Alcañiz Boada; Karin Sundström; Javier Cortés; F Xavier Bosch Josë; Kate Cuschieri; Joakim Dillner; Jesper Bonde
Journal:  BMC Cancer       Date:  2020-05-06       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.